
Winter 2002
Ansgar Brock*, David M. Horn, Christopher M. Shaw, Eric C. Peters, Christer Ericson, Qui Phung, Scott B. Ficarro, Arthur R. Salomon, *Genomics Institute of the Novartis Research Foundation
Scott E. Mackler, Cleanroom Consulting, LLC
Angela Berns, Amgen, Inc.
Joseph F. Noferi, Esq., Edward R. Arling and Ralph L. Dillon, Pharmacia Corporation
Yunsheng Hsieh*, Ph.D., Kwokei Ng, Ph.D., and Walter A. Korfmacher, Ph.D., Drug Metabolism and Pharmacokinetics Department, Schering-Plough Research Institute
George Zhou, Ph.D., Jian Wang*, Ph.D., Zhihong Ge, Ph.D., Yongkui Sun, Ph.D.,Merck Research Laboratories, Merck & Co., Inc.
Theodore W. Randolph, Ph.D.1 & James A. Searles, Ph.D.2, 1University of Colorado, Boulder, 2Eli Lilly & Co.
Emil W. Ciurczak, Consultant
David J. Hauss, Ph.D., Eli Lilly and Company
Stanley S. Davis, Ph.D., Institute of Pharmaceutical Sciences, University of Nottingham
Sherri Matis, Ph.D., Nick Brown and Gayathri Ramabadran, AstraZeneca Pharmaceuticals
Glenn Van Buskirk, Ph.D., Thomas P. Layloff, Ph.D., Jerome P. Skelly, Ph.D., & Francis H. Zenie
Carol Noory, Nhan Tran, Ph.D., Larry Ouderkirk, and Vinod Shah, Ph.D., Food and Drug Administration, Center for Drug Evaluation and Research
Joseph P. Reo, Ph.D. and Jennifer K. Fredrickson, Pharmacia Corporation
Vicky Kett, Ph.D,.The School of Pharmacy, Queen's University of Belfast